Recruiting
Early Phase 1

Beta-Adrenergic Receptors

Sponsor:

University of Missouri-Columbia

Code:

NCT06417177

Conditions

Aging

Menopause

Hypoxia

Vasodilation

Eligibility Criteria

Sex: Female

Age: 18 - 70

Healthy Volunteers: Accepted

Interventions

Placebo

Propranolol

Gemtesa

Study Details

Brief summary:

The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.

Conditions

Aging

Menopause

Hypoxia

Vasodilation

Study ID

NCT06417177

Start date

Jun 3, 2024

Status verified date

Sep, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Female assigned at birth
  • Pre, peri- or post-menopausal
  • Healthy weight (BMI ≥18 and ≤30 kg/m2)

Exclusion Criteria:

  • Male (assigned at birth)
  • Pregnancy, breastfeeding
  • Use of hormone replacement therapies
  • Hysterectomy
  • Body mass index >30 kg/m2
  • Diagnosed sleep apnea
  • Current smoking/Nicotine/Drug use
  • Nerve/neurologic disease
  • Cardiovascular, hepatic, renal, respiratory disease
  • Blood pressure ≥140/90 mmHg
  • Diabetes, Polycystic ovarian syndrome
  • Communication barriers
  • Prescription medications
  • Malignant cancer

Study Design

Enrollment

75 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Hypoxia

Participants will be exposed to hypoxia (low oxygen air) using a mask.

experimental: Cold pressor test

Participants will be exposed to the cold pressor test (ice water on the foot).

experimental: Hypercapnia

Participants will be exposed to hypercapnia (high carbon dioxide air) using a mask.

Interventions

Placebo

Participants will receive a placebo in pill form.

Propranolol

Participants will receive oral propranolol (1 mg/kg).

Gemtesa

Participants will receive oral gemtesa (75 mg).

Primary outcome measure

  • Forearm blood flow [ Time Frame: Change from baseline to 5 minutes. ]

Central Contacts and Locations

Central contacts

Jacqueline Limberg

573-882-2544limberglab@missouri.edu

Locations

University of Missouri-Columbia

Recruiting

Columbia, Missouri, United States, 65211

Contacts

Jacqueline K Limberg, Ph.D.

573-882-2420limbergj@missouri.edu

More Information

Sponsor

University of Missouri-Columbia

Last update posted

Sep 10, 2026

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-14. This information was provided to ClinicalTrials.gov by University of Missouri-Columbia on 2026-09-10. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.